Effective price per mg uses an active dated override first, then the row-level historical discount, then the latest vendor-default policy recorded for that UTC day. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.

Price watch · beta

Let the market come to you.

Watch the best market price or one vendor. Get one email when KPV crosses your target, drops, or sets a new tracked low—without daily noise.

Price scope Alert me Target per mg

$/mg

Confirmed Weekly Peptide Intel email

Requires a confirmed Weekly Peptide Intel address, then a separate alert confirmation. Already watching? Manage price alerts. Public prices can change; confirm the final cart total.

Public product evidence 235 certificate records for KPV products, from 91 vendors 154 reference a report on the testing laboratory's own system · 109 have a laboratory lookup that answered when last checked · 216 match a vendor product page at the same address

Status

Research Market

This name primarily lives in the research market and should not be read like an approved pharmaceutical product.

Research area

Tissue-repair research

Primary research area: Tissue repair. Also surfaces under Immune · Dermal for browsing and discovery.

Body systems

Gut · Immune · Skin

Where the compound acts, as a browse axis. It is an editorial grouping for discovery, not a claim about labeled indications.

Aliases

No major aliases are tracked for this profile yet.

Signal depth

Low

No FDA label signal · 0 trials · 135 PubMed results

Preclinical

Research evidence

Current evidence for KPV is limited to laboratory or animal studies — there are no name-matched human trials with reported results. Any claims about effects in people are not yet backed by clinical data.

KPV has no clinical trials that name it and 135 PubMed-indexed publications and is not FDA-approved. Current evidence is preclinical or mechanistic.

Human data

Lab / animal only

Trial quality

No human trials

Outcomes

No human trials

Replication

Multiple papers

Literature

High-impact

Molecular Therapy · 184 citations Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis Solar Energy · 122 citations KPV: A clear-sky index for photovoltaics Gastroenterology · 119 citations PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation Journal Article Lysine-Proline-Valine attenuates oxidized low-density lipoprotein-induced foam cell formation and inflammatory responses in RAW264.7 macrophages. Journal Article Synthetic Peptides in Pharmacy Compounding: Analysis of PCAC Recommendations and Industry Safety Standards. Journal Article KPV attenuates adipogenesis and lipid metabolism through modulation of ROS-mediated AKT/mTORC1/PPARγ signaling.

Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-11-07 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What KPV is

KPV is a short peptide fragment that often appears in gut-health, inflammation, and repair-oriented product lines. It is especially common in blends marketed around recovery or skin support.

Why it matters

KPV shows how the recovery category extends beyond tendon-and-muscle peptides into gut and inflammatory signaling.

Regulatory context

KPV is not FDA approved in the United States and is best treated as a research-market peptide.

Practical reading note

If a vendor frames KPV as a cure-all, that is usually a sign to slow down and separate plausible mechanistic interest from broad consumer claims.